📊 Q3 Earnings are here! Plan ahead with key data on upcoming stock reports - all in 1 placeSee list

CSPC Pharmaceutical Group Ltd (1093)

Hong Kong
Currency in HKD
Disclaimer
7.19
+0.47(+6.99%)
Delayed Data
1093 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
High dividend Yield
Fair Value
Day's Range
6.837.22
52 wk Range
4.457.83
Bid/Ask
7.19 / 7.20
Prev. Close
6.72
Open
6.95
Day's Range
6.83-7.22
52 wk Range
4.45-7.83
Volume
149,580,336
Average Volume (3m)
89,047,978
1-Year Change
21.74%
Fair Value
Unlock
Fair Value Upside
Unlock
1093 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
8.14
Upside
+13.21%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 10 consecutive years
Show more

CSPC Pharmaceutical Group Ltd Company Profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People’s Republic of China.

Employees
23500
Market
Hong Kong

Compare 1093 to Peers and Sector

Metrics to compare
1093
Peers
Sector
Relationship
P/E Ratio
12.8x19.0x−0.6x
PEG Ratio
−5.400.280.00
Price/Book
2.2x1.8x2.6x
Price / LTM Sales
2.4x2.3x3.3x
Upside (Analyst Target)
20.6%13.2%49.0%
Fair Value Upside
Unlock8.6%7.7%Unlock

FAQ

What Is the CSPC Pharma (1093) Stock Price Today?

The CSPC Pharma stock price today is 7.19

What Stock Exchange Does CSPC Pharma Trade On?

CSPC Pharma is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for CSPC Pharma?

The stock symbol for CSPC Pharma is "1093."

Does CSPC Pharma Pay Dividends? What’s The Current Dividend Yield?

The dividend yield is 4.46%.

What Is the CSPC Pharma Market Cap?

As of today, CSPC Pharma market cap is 83.80B.

What is CSPC Pharma Earnings Per Share?

The CSPC Pharma EPS is 0.50.

What Is the Next CSPC Pharma Earnings Date?

CSPC Pharma will release its next earnings report on 18 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.